Is HRMY a good stock to buy? We came across a bullish thesis on Harmony Biosciences Holdings, Inc. on r/StockPickNews by EaseQuiet529. In this article, we will summarize the bulls’ thesis on HRMY. Harmony Biosciences Holdings, Inc.’s share was trading at $34.10 as of June 9th. HRMY’s trailing and forward P/E were 13.75 and 10.81 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. HRMY is emerging as a compelling opportunity in the biopharma space following a period of market underappreciation, with its current valuation failing to reflect the strength of its core asset and growth pipeline.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Trading around $27.70–$27.80 with a modest market capitalization of approximately $1.6 billion, the stock appears significantly discounted relative to its fundamentals, as evidenced by a low trailing P/E of ~7.8x and forward P/E of ~11.4x, alongside a PEG ratio of just 0.38.
The company’s flagship drug, WAKIX, remains the cornerstone of its investment thesis, with management reaffirming 2026 revenue guidance of $1.0 billion to $1.04 billion, positioning the drug to achieve blockbuster status. This milestone not only reinforces the durability of its revenue base but also highlights the scalability of its commercial platform. Harmony Biosciences benefits from strong unit economics, including a robust 77% gross margin, and operates as a self-funded entity, reducing reliance on external capital and limiting shareholder dilution.
Beyond WAKIX, the pipeline provides additional upside, with a New Drug Application for Pitolisant GR expected in Q2 2026 and a Phase 3 topline data readout anticipated in the second half of the year, both serving as meaningful catalysts. With analyst price targets ranging from $42 to $47, implying roughly 50–60% upside, the stock offers an attractive risk-reward profile supported by earnings growth, pipeline optionality, and operational strength, making it a high-conviction bullish opportunity.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted the potential of Casgevy as a blockbuster gene-editing therapy, strong net cash position, and a robust pipeline driving significant upside. CRSP’s stock price has appreciated by approximately 25.65% since our coverage. EaseQuiet529 shares a similar view but emphasizes on Harmony Biosciences’ undervaluation, strong WAKIX revenue visibility, and near-term pipeline catalysts.
Harmony Biosciences Holdings, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held HRMY at the end of the first quarter which was 37 in the previous quarter. While we acknowledge the risk and potential of HRMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HRMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
